《抗体靶向治疗药物》VIP免费

.抗体靶向治疗药物抗体靶向治疗药物. 邵荣光，甄永苏： 抗体靶向治疗药物 见：王晓良主编. 应用分子药理学. 中国协和医科大学出版社，北京，2005甄永苏，邵荣光主编： 抗体工程药物 化学工业出版社，北京，2002..LYMPHOCYTE HYBRIDOMA MYELOMAB 淋巴细胞杂交瘤技术.Mechanism of Action: Monoclonal AbMalignantcellMonoclonal AbTumor specific AgComplementKillerleukocyteADCC(Ab dependent cell-mediated cytotoxicity)CDC(Complement dependent cytotoxicity)Monoclonal AbLigand dependent apoptosis..Graphic representation of progression of monoclonal antibodies from murine to chimeric to humanized to PRIMATIZED® and human. The more human the antibody is, the less likely it will generate an immune response and the more utility it has for chronic (repeat) therapy.Generations of antibody technology..与单抗偶联的常用与单抗偶联的常用“弹头弹头”药物药物 毒素植物 蓖麻毒素，相思豆毒素，saporin ，gelonin ，modecin 等微生物 绿脓杆菌外毒素，白喉毒素 药物抗代谢类 氨基蝶呤，MTX ，Ara-C ，5-FU ，5- 氟脱氧尿苷等蒽环类 阿霉素，柔红霉素，去甲氧柔红霉素，吗啉阿霉素等烷基化类 苯丙氨酸氮芥，苯丁酸氮芥，丝裂霉素C ，顺铂等抗有丝分裂 长春花碱，秋水仙碱，鬼臼毒素等.Physical characteristics of some therapeutic radionuclides碘砹铋镧铜...Monoclonal antibodies in the order of FDA-approval2006 Panitumumab (Vectibix®) EGFR Humanized IgG2 Colorectal cancer2006 Ranibizumab (Lucentis®) VEGF-A Humanized IgG1 AMD ( 黄斑变性）FDA: 35 SFDA: 11 >15BUS ＄ >1/3 BIO.US and EU therapeutic mAb approvals to date.1, chimeric mAbs, all products (n = 39); 2, oncological chimeric mAbs (n = 21); 3, immunological chimeric mAbs (n = 9); 4, chimeric mAbs, 1987–1997 (n = 20); 5, humanized mAbs, all products (n = 102); 6, oncological humanized mAbs (n = 46); 7, immunological humanized mAbs (n = 34); 8, humanized mAbs, 1988–1997 (n = 46). Data are presented...